- STAT+: Trump’s obesity drug plan creates a temporary Medicare program that may be hard to endAfter July 1, Medicare will offer GLP-1 weight-loss drugs for $50. It's supposed to be temporary, but chances are it won't be.STAT · 1mo ago↗ source
- Gan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma dataPlus news about Sanofi, PharmaMar, Jazz, Rhythm Pharmaceuticals, Spyre and Zymeworks 🇨🇳 Another obesity readout from China: Gan & Lee Pharmaceuticals, a China-based insulin specialist, anno…Endpoints · 1mo ago↗ source
- STAT+: A key European clinical trial registry lacks complete and timely results, an analysis findsA new analysis found that results for less than half of the clinical studies registered in a key European database were reported within the required time frame.